Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

Author(s):
Schaik, I.N. van; Bril, V.; Geloven, N. van; Hartung, H.P.; Lewis, R.A.; Sobue, G.; Lawo, J.P.; Praus, M.; Mielke, O.; Durn, B.L.; Cornblath, D.R.; Merkies, I.S.J.; PATH Study Grp
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-01-31
Language
English
Is part of
The Lancet Neurology (2018), Vol. 17, no. 1, p. 35-46
hdl
1887/86242
doi
10.1016/S1474-4422(17)30378-2